Reveromycin A is an osteoclast-targeting antibiotic compound that exhibits anti-resorptive and antifungal activities. In animal models of juvenile Paget’s disease, reveromycin A inhibits bone resorption and normalizes bone turnover and formation. Reveromycin A inhibits isoleucyl-tRNA synthase, preventing protein synthesis in osteoclasts; this induces apoptosis and prevents resorption in vivo. Additionally, reveromycin A inhibits bone metastasis by lung cancer cells.

**References**

